Refine USA secures key approval to use Rejuvapen NXT to treat facial wrinkles

Refine USA has secured key approval to expand the usage of its medical grade micro-needling device Rejuvapen NXT to treat facial wrinkles.

The company received a class II medical clearance from US Food and Drug Administration (FDA) to expand the usage of the device.

Refine USA Sales president Anthony Johnson said: “Our recent FDA clearance for the patent pending Rejuvapen NXT is without a doubt, a game changer in the industry. Our device brings major technological advancements to the market with its multiple (9) speed settings, precise infinite dial, and digital motor.

“The health care provider now has the flexibility to customise each patient’s facial treatment to produce the consistent clinical results today’s consumers demand.

“We are proud to announce the Rejuvapen NXT is manufactured in the USA and we have positioned our unit and consumable pricing to be nearly 50% less than the other FDA cleared microneedling systems available today.”

Equipped with 12 stainless steel tips, the Rejuvapen NXT is designed to help in improving appearance in a short procedure time.

According to the company, the device is safe and effective for all skin types as well as causes little pain and discomfort.

Additionally, Rejuvapen NXT has cleared several electrical and safety tests for biocompatibility including design verification and validation testing.

Headquartered at Jacksonville Beach in Florida, Refine USA is involved in delivering cosmetic medical aesthetic devices since 2006.

Its product portfolio also includes PureSpin PRP product line, the Kimera Exosome product line and Ontogeny C growth factor products, amongst others.